GPP
VRDN icon

Great Point Partners’s Viridian Therapeutics VRDN Stock Holding History

Great Point Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-750,000
Closed -$10.1M – 36
2025
Q1 		$10.1M Hold
750,000
– – 5.36% 5
2024
Q4 		$14.4M Hold
750,000
– – 6.78% 4
2024
Q3 		$17.1M Buy
750,000
+250,000
+50% +$4.09M 5.02% 5
2024
Q2 		$6.5M Sell
500,000
-835,000
-63% -$11.6M 1.25% 25
2024
Q1 		$23.4M Buy
+1,335,000
New +$25.9M 3.64% 9

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Great Point Partners's VRDN Position: Q2 2025 in Review

Great Point Partners sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 750,000 shares — an estimated $10.1M sold.

Great Point Partners first reported a position in VRDN in Q1 2024 and held it in 5 quarters. The position peaked at $23.4M in Q1 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Great Point Partners reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Great Point Partners sold 750,000 Viridian Therapeutics shares in Q2 2025, an estimated $10.1M.
  • Great Point Partners first reported a position in Viridian Therapeutics in Q1 2024 and held it in 5 quarters.
  • Great Point Partners's Viridian Therapeutics position peaked at $23.4M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Great Point Partners's 13F filing for Q2 2025, filed 14 Aug 2025.